Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2007 2
2008 2
2009 3
2010 1
2011 2
2012 2
2013 2
2014 2
2015 3
2016 1
2017 2
2018 2
2019 1
2020 3
2021 3
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
MRI features of breast implant-associated anaplastic large cell lymphoma.
Rotili A, Ferrari F, Nicosia L, Pesapane F, Tabanelli V, Fiori S, Vanazzi A, Meneghetti L, Abbate F, Latronico A, Cassano E. Rotili A, et al. Among authors: vanazzi a. Br J Radiol. 2021 Sep 1;94(1125):20210093. doi: 10.1259/bjr.20210093. Epub 2021 May 21. Br J Radiol. 2021. PMID: 33989039 Free PMC article. Review.
Rituximab in Hodgkin lymphoma: is the target always a hit?
Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA. Saini KS, et al. Among authors: vanazzi a. Cancer Treat Rev. 2011 Aug;37(5):385-90. doi: 10.1016/j.ctrv.2010.11.005. Epub 2010 Dec 22. Cancer Treat Rev. 2011. PMID: 21183282 Review.
In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in a new era of rationally designed targeted agents in cancer therapeutics. ...
In 1997, the anti-CD20 monoclonal antibody (MAb) rituximab became the first MAb approved for clinical use in oncology, and ushered in …
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, Derenzini E. Mazzara S, et al. Among authors: vanazzi a. Blood Adv. 2023 Feb 28;7(4):630-643. doi: 10.1182/bloodadvances.2022007825. Blood Adv. 2023. PMID: 36806558 Free PMC article.
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Conconi A, Chiappella A, Ferreri AJM, Stathis A, Botto B, Sassone M, Gaidano G, Balzarotti M, Merli F, Tucci A, Vanazzi A, Tani M, Bruna R, Orsucci L, Cabras MG, Celli M, Annibali O, Liberati AM, Zanni M, Ghiggi C, Pisani F, Pinotti G, Dore F, Esposito F, Pirosa MC, Cesaretti M, Bonomini L, Vitolo U, Zucca E. Conconi A, et al. Among authors: vanazzi a. Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251. Blood Adv. 2024. PMID: 38181782 Free PMC article. Clinical Trial.
Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G, Vanazzi A, Radice D, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D. Andreola G, et al. Among authors: vanazzi a. Transfus Apher Sci. 2012 Aug;47(1):27-32. doi: 10.1016/j.transci.2012.03.004. Epub 2012 Apr 4. Transfus Apher Sci. 2012. PMID: 22480954
High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E, Peccatori F, Vanazzi A, Piperno G, Calabrese L, Botteri E, Travaini L, Preda L, Martinelli G. Cocorocchio E, et al. Among authors: vanazzi a. Hematol Oncol. 2013 Mar;31(1):34-40. doi: 10.1002/hon.2014. Epub 2012 Mar 30. Hematol Oncol. 2013. PMID: 22473680
We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients …
We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto …
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Taverna C, et al. Among authors: vanazzi a. J Clin Oncol. 2016 Feb 10;34(5):495-500. doi: 10.1200/JCO.2015.61.3968. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712227 Free PMC article. Clinical Trial.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: vanazzi a. Blood Adv. 2020 Dec 8;4(23):5951-5957. doi: 10.1182/bloodadvances.2020002858. Blood Adv. 2020. PMID: 33275769 Free PMC article. Clinical Trial.
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Witzig TE, et al. Among authors: vanazzi a. Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764. Ann Oncol. 2018. PMID: 29253068 Free article. Clinical Trial.
33 results